Sun Pharma Share Price Target 2026, 2027, 2028, 2029, 2030

Sun Pharma share price today

Sun Pharmaceutical (NSE: SUNPHARMA) is India’s largest drugmaker, and for the past few years it has been quietly changing what kind of company it is. The old Sun sold generics by the tonne and lived with generic-industry economics. The new Sun earns an increasing share of profit from global specialty brands — Ilumya in psoriasis, Cequa in dry eye, Leqselvi in alopecia — products with patents, pricing power and 30% operating margins attached.

At 37.6× earnings, the market has noticed. The question is what that price already assumes and how much of the specialty transition still remains unrecognised at ₹1,964.

From volume to value

Specialty is the whole thesis. Generic drugs are a treadmill: price erosion every year, offset only by new launches. Specialty brands compound instead — a dermatology franchise grows for a decade. Sun’s specialty revenue has become the swing factor in its mix, and it is why operating margin sits near 30% while five-year profit growth (16.7% CAGR) has outrun sales growth (11.8%).

What matters next: US FDA inspections (the perennial Indian pharma risk), the pace of specialty ramp against R&D spend, and a promoter pledge of 1.65% — small, but worth knowing exists.

The numbers

Financial snapshot — 5 August 2026

Metric	Value
Market cap	₹4,74,492 Cr
P/E (TTM)	37.6
EV/EBITDA	23.3
Operating margin	29.8%
ROE / ROCE	16.0% / 20.5%
Debt to equity	0.06
Sales CAGR (5y)	11.8%
Profit CAGR (5y)	16.8%
Promoter holding	54.5% (1.65% pledged)
EPS (TTM)	₹52.3

Sun Pharma share price target 2026 to 2030

EPS base ₹52.3 (TTM). Bear: specialty ramp stalls and an FDA setback bites — 8% growth, multiple compresses to 26×. Base: specialty keeps mixing margins up — 13% growth at 32×. Bull: a specialty asset breaks out globally — 17% growth at 38×.

Base case from ₹1,964: ≈ +57% over four and a half years plus dividends — solid rather than spectacular. The bear case is nearly flat. The upside case needs specialty to surprise because the existing multiple already recognises Sun’s market leadership and improved earnings quality.

What supports the case

1. India’s #1 pharma company by scale — and scale in pharma buys distribution, manufacturing depth and regulatory muscle.
2. Specialty portfolio changes the earnings quality — brands, not commodity generics, now drive the mix.
3. ~30% OPM with near-zero debt (D/E 0.06).
4. 20.5% ROCE, improving with the mix.
5. A domestic branded business that compounds quietly beneath the US story.

The risks: FDA inspection outcomes can hit any plant, specialty R&D is expensive with binary outcomes, and 37× leaves little room for a flat year.

What to weigh at the current price

The tension is whether Ilumya, Cequa, Leqselvi and future specialty assets can outrun R&D and regulatory risk before 37.6× earnings begins to look expensive for a slower year.

FAQ

What is the Sun Pharma share price target for 2030? The table above sets out bear, base and bull scenarios for each year to 2030. They are valuation sensitivities, not promised prices.

Why does Sun Pharma trade richer than other Indian pharma companies? The specialty-brand mix. Patented dermatology and ophthalmology franchises earn better, steadier margins than commodity generics, and the market pays up for that quality.

What is Sun Pharma’s biggest risk? US FDA compliance — an adverse inspection at a key plant can interrupt supply and sentiment simultaneously.

When are Sun Pharma’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.